Nanomedicine and Nano Device Pipeline Surges 68%

Jan 04, 2006, 00:00 ET from National Health Information, LLC

    ATLANTA, Jan. 4 /PRNewswire/ -- According to data compiled in the just-
 released NanoBiotech News 2006 Nanomedicine, Device & Diagnostic Report, 130
 nanotech-based drugs and delivery systems and 125 devices or diagnostic tests
 have entered preclinical, clinical, or commercial development, meaning the
 clinical pipeline has grown 68% since last year at this time.
     NanoBiotech News 2006 Nanomedicine, Device & Diagnostic Report, produced
 by the publishers of NanoBiotech News, includes the associated company or
 academic research center name, product name, type, indication and status for
 each of the 255 entries. Additionally, key experts provide in-depth analysis
 of the state of the industry and the products currently under development.
 This executive briefing is the only resource to compile a comprehensive status
 report of all nano-based drugs and medical devices, providing a remarkable
 look at the market's quickening pulse.
     "What we're seeing is a growing community of nanobiotech drug and device
 developers who are digging in their heels -- and surviving," says Lynn Yoffee,
 associate publisher of NanoBiotech News, which produced the 2006 Nanomedicine,
 Device & Diagnostic Report. "Along with that comes the advance of numerous
 product candidates marching beyond concept well into trials, ever closer to
 market. The industry is experiencing an evolution similar to what we saw in
 biotechnology, but the nanobiotech developers are putting together therapies
 and diagnostics with an even more astonishing 'wow' factor." Some of those
 promising products include:
      * A nanoviricide for Avian flu
      * Nano-based coatings for medical implants that will permit safe magnetic
        resonance imaging
      * A multifunctional nano device that selectively binds to cancer tumor
        cells and destroys them
     "Although we keep a very close eye on the progress of drug candidates, we
 know the most immediate impact of nanotechnology in health care will be seen
 in earnest within the next couple of years in the form of medical devices.
 It's less complicated to get them developed and through the regulatory
 process," says Yoffee.
     A plethora of new deals brewed in 2005. Nearly a third (30%) of all
 products are being developed as part of collaborations or licensing deals,
 another trend similar to the biotechnology industry growth.
     But during tough markets, only the top deals attract capital, says Douglas
 W. Jamison, president of New York venture capital firm Harris & Harris Group,
 Inc. When the market opens up, marginal companies also receive funding -- not
 necessarily a positive event for the market but certainly good news for start-
 up companies. From a capitalization standpoint, the biggest news during 2005
 was the introduction of $20 million series A financings, which allowed
 companies to move their technologies into phase II clinical trials, Jamison
 says. But without new players coming into the nanobiotech market, the same
 investors are putting money into these deals.
     Consequently, he expects to see fewer early stage deals in 2006 and a
 corresponding weed-out of nanobiotech start-ups.
     "This could be the winnowing year for nanobiotech," Jamison says. "The
 cream will rise, and others will fail to receive second and third rounds of
 funding. In fact, that's already starting to occur."
     Industry observers and participants alike can stay on top of the field by
 reading NanoBiotech News every week. Every major nanomedicine development --
 from both business and scientific perspectives -- is covered in this global
 nanobiotechnology intelligence source. The 2006 Nanomedicine, Device &
 Diagnostic Report is available for free to NanoBiotech News subscribers. To
 order a copy of the report, available for only $199, or to get a free trial
 subscription to the newsletter, visit or call
 (404) 607-9500 or (800) 597-6300.

SOURCE National Health Information, LLC